A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. · Hypothalamic Obesity
Phase 3
Active, not recruiting
143
2026-05
Industry sponsor intelligence
Rhythm Pharmaceuticals, Inc.Clinical Pipeline.
Lead-sponsor view of Rhythm Pharmaceuticals, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 23
- Recruiting
- 1
- Active
- 3
- Completed
- 18
- Results posted
- 14
- Avg enrollment
- 74
Pipeline overview
Programs by phase and activity.
Velocity
Rhythm Pharmaceuticals, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
24phase labels
Early Phase 10
Phase 14
Phase 29
Phase 310
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Setmelanotide → | 23 | 4 | 9 | 10 | 1 | 4 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Rhythm Pharmaceuticals, Inc. · Hypothalamic Obesity · Multiple Pituitary Hormone Deficiency Genetic Form
Phase 3
Recruiting
39
2026-02
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Rhythm Pharmaceuticals, Inc. · Prader-Willi Syndrome · Obesity
Phase 2
Active, not recruiting
18
2026-02
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Rhythm Pharmaceuticals, Inc. · Obesity · Genetic Obesity
Phase 3
Active, not recruiting
296
2026-02
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Open-Label Extension Study of Setmelanotide
Rhythm Pharmaceuticals, Inc. · Obesity Associated With Defects in Leptin-melanocortin Pathway
Phase 3
Completed
28
2026-07
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Rhythm Pharmaceuticals, Inc. · Genetic Obesity
Phase 2
Completed
164
2025-07
Long Term Extension Trial of Setmelanotide
Rhythm Pharmaceuticals, Inc. · Obesity Associated With Defects in Leptin-melanocortin Pathway
Phase 2 / Phase 3
Completed
205
2025-05
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. · Hypothalamic Obesity
Phase 2
Completed
18
2025-02
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals, Inc. · Bardet-Biedl Syndrome · POMC Deficiency Obesity
Phase 3
Completed
12
2024-11
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Rhythm Pharmaceuticals, Inc. · Bardet-Biedl Syndrome · POMC Deficiency
Phase 3
Completed
19
2024-11
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
Rhythm Pharmaceuticals, Inc. · Healthy
Phase 4
Completed
77
2024-05
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Rhythm Pharmaceuticals, Inc. · Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)
Phase 3
Completed
52
2023-12
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Rhythm Pharmaceuticals, Inc. · Pro-opiomelanocortin (POMC) Deficiency Obesity
Phase 3
Completed
15
2023-09
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Rhythm Pharmaceuticals, Inc. · Genetic Obesity · Obesity
Phase 2
Completed
213
2023-08
Showing 10 of 18 studies
Search sponsor records
All Rhythm Pharmaceuticals, Inc. studies.
This page groups studies where Rhythm Pharmaceuticals, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
23 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06596135Open-Label Extension Study of SetmelanotideJul 15, 2026NCT05774756A Trial of Setmelanotide in Acquired Hypothalamic ObesityMay 29, 2026NCT06760546A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)Feb 12, 2026NCT06772597A Study of Setmelanotide in Patients With Prader-Willi SyndromeFeb 12, 2026NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayFeb 10, 2026NCT04963231DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayJul 2, 2025NCT03651765Long Term Extension Trial of SetmelanotideMay 31, 2025NCT04725240Open-Label Study of Setmelanotide in Hypothalamic ObesityFeb 7, 2025NCT04966741Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNov 27, 2024NCT05194124Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayNov 26, 2024